0001127602-14-035924.txt : 20141223
0001127602-14-035924.hdr.sgml : 20141223
20141223161331
ACCESSION NUMBER: 0001127602-14-035924
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141219
FILED AS OF DATE: 20141223
DATE AS OF CHANGE: 20141223
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: BIOCRYST PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0000882796
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 621413174
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2190 PARKWAY LAKE DR
CITY: BIRMINGHAM
STATE: AL
ZIP: 35244
BUSINESS PHONE: 2054444600
MAIL ADDRESS:
STREET 1: 2190 PARKWAY LAKE DR
CITY: BIRMINGHAM
STATE: AL
ZIP: 35244
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Babu Yarlagadda S
CENTRAL INDEX KEY: 0001452635
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-23186
FILM NUMBER: 141307045
MAIL ADDRESS:
STREET 1: 2190 PARKWAY LAKE DR
CITY: BIRMINGHAM
STATE: AL
ZIP: 35244
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2014-12-19
0000882796
BIOCRYST PHARMACEUTICALS INC
BCRX
0001452635
Babu Yarlagadda S
4505 EMPEROR BLVD.
SUITE 200
DURHAM
NC
27703
1
Senior VP - Drug Discovery
Emp. Stock Option (Right to Buy)
5.45
2014-12-19
4
A
0
17000
0
A
2014-12-19
2023-08-08
Common Stock
17000
17000
D
On December 19, 2014, the U.S. Food and Drug Administration (FDA) approved RAPIVAB (peramivir injection), an intravenous (i.v.) neuraminidase inhibitor for the treatment of acute uncomplicated influenza in patients 18 years and older who have been symptomatic for no more than two days. As a result, one of the vesting criteria associated with the performance-based stock options awarded to all employees in August 2013 has been met. Therefore, 25% of the performance-based stock options vested on December 19, 2014.
/s/ Alane P. Barnes, by power of attorney
2014-12-23